JPM vs QQQX
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
JPM exhibits a concerning Piotroski F-Score of 2/9, indicating weak short-term fundamental health, and currently trades at a significant premium to both its Graham Number ($239.11) and Intrinsic Value ($140.07). While the company maintains a strong ROE of 16.13% and dominant market positioning, negative YoY earnings growth (-3.60%) and bearish insider activity from the CEO and CFO signal internal caution. The stock's current price of $313.68 suggests the market is pricing in a growth premium that is not currently supported by the deterministic health or value metrics.
The fund exhibits a critical Piotroski F-Score of 1/9, indicating severe fundamental weakness by deterministic standards, although this is typical for closed-end fund structures. While historical price performance is strong (1Y +43.7%), the asset is currently trading at a premium to its intrinsic value of $26.25. A stark divergence exists between the near-52-week high price and a very bearish technical trend score of 10/100. The primary attraction remains the robust 8.32% dividend yield, which provides a significant income cushion.
Compare Another Pair
Related Comparisons
JPM vs QQQX: Head-to-Head Comparison
This page compares JPMorgan Chase & Co. (JPM) and Nuveen Nasdaq 100 Dynamic Overwrite Fund (QQQX) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.